Innovus Pharma Announces Official Launch of its Amazon®, Walmart®, eBay® and Wish® On-Line Stores with a Combined 116 Product SKUs

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced the official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs. As part of this on-line product distribution, the Company also secured worldwide non-exclusive rights to sell two primary products from Antiaging Systems, Ltd.: Can-C™ and Melatonin (MZS™).

The launch of the U.S. on-line stores adds to Innovus Pharma’s substantial on-line sales presence and expands its other on-line websites and its Beyond Human® platform, which currently include over 160 websites and over 2.5 million subscribers.

"We are very excited to announce the official launch of our Amazon®, Walmart®, eBay® and Wish® on-line stores with our current combined 116 product SKUs,” said Innovus CEO Dr. Bassam Damaj. "We are already seeing a significant increase in our month over month sales from the on-line stores and we currently expect the on-line sales to be a growing percentage of our revenues in the very near future.

"In addition, we are working on the development and launch of additional Amazon® sites in Canada, Mexico and the United Kingdom and we look forward to growing our on-line presence of our products and additional products such as Can-C™ and Melatonin (MZS™) that already have large on-line sales presences with Can-C™ alone generating on average across all sellers on Amazon® around $1.2 million per year in 2017. These additional sales channels should only serve to increase the overall sales revenues we may see in the future through our ever-growing online channels,” he continued.

About Can-C™ Eye Drops

Can-C™ eye drops, made by Antiaging Systems, Ltd., are the original N-acetylcarnosine (often shorted to "NAC”) eye drop formula developed to normalize senile cataract impairment.

Users and scientists have reported that Can-C™ is also great for:

• Dry eye syndrome.
• Benefit for those who wear contact lenses, particularly soft contact lenses. (Not only do the lubricants in Can-C™ help contact lenses feel more comfortable, but N-acetylcarnosine is also believed to inhibit the buildup of lactic acid in the eye, meaning you can wear them in comfort for longer.)
• Corneal disorders.
• Computer vision syndrome.
• Eye strain.
• Ocular inflammation.
• Blurred vision.
• Presbyopia.
• Retinal diseases.
• Vitreous opacities and lesions.
• Complications of diabetes mellitus and other systemic diseases.
• Open-angle primary glaucoma.

Cataract surgery is the most commonly performed operation in the world with over 1.5 million operations in the United States alone every year. Although generally safe, there is still a complication rate of 30% to 50% of patients who develop opacification of the posterior lens capsule within two years and require further laser treatment. Can-C™ cataract eye drops have helped thousands of people normalize their cataracts without surgery, leaving the natural lens in place rather than an artificial one.

Human trials on people suffering from senile cataract, using a twice daily dose of Can-C™ for six months showed the following results:

• 88.9 percent of patients had improved glare sensitivity;
• 90 percent reported improved visual acuity – clearer and sharper vision; and
• Perhaps most significantly, 41 percent of patients experienced a significant improvement in lens ‘transmissivity.’

And while the patients were taking the NAC carnosine eye drops, the lead researcher noted that there was no recurrence of cataract.

About Melatonin (MZS™)

Melatonin (MZS™) is made by Antiaging Systems Ltd. and its main ingredient, melatonin, is vital to protect a person’s hormonal system, regulate immunity and repair the body’s cells.

It is commonly used by shift workers and also to treat jet lag and age-related sleep disorders, but its abilities go far beyond simply its sleep-inducing properties. Other benefits of the product are its use as an antioxidant, for longevity and for age related macular degenerations.

Melatonin’s effect on longevity is well documented; in fact laboratory tests on rats and mice have demonstrated that melatonin increased their lifespans by 20%. Numerous experts believe melatonin is a vital anti-aging product because of its positive effect on the aging immune system, its protection of the cardiovascular system, its ability to increase growth hormone production and above all its capacity to limit free radical damage.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Amazon® is a registered trademark of Amazon.com, Inc. (NASDAQ: AMNZ); eBay® is a registered trademark of eBay, Inc. (NASDAQ: EBAY); Walmart® is a registered trademark of Wal-mart Stores, Inc. (NYSE: WMY); and Wish® is a registered trademark of ContextLogic, Inc.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sales of its products through its Amazon® stores and through its other on-line channels, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180118005466/en/